In a genome-wide association study, variants in both the ABO blood group locus and a cluster of genes on human chromosome 3 are more common among COVID-19 patients with respiratory failure than in the general population.
Dozens of intranasally delivered vaccines targeting SARS-CoV-2 are in development. Could they pave the way for widespread nasal vaccination in the future?